Importantly, a statistical analysis of variance (ANOVA) comparison of tumor volumes on Day 30 determined that the synergy of the antitumor effects was only maintained in the “Triplet” Ad-p53 + CD122/132 + anti-PD-1 treatment combination (p value <0.0001 overall and p value <0.0001 separately compared to every other treatment group). This evidence concerns the gene TP53 and neoplasm.